A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a 'pre-pandemic' influenza vaccine is underway. Investigators are evaluating whether imiquimod cream, commonly used to treat genital warts and certain skin cancers, can boost the body's immune response to an H5N1 influenza vaccine. The trial is enrolling 50 healthy adults ages 18-50 years.
New research shows there's promise in specific immune system peptides -- amino acid compounds that signal cells how to function. In this case, they may be affecting brain activity and, by extension, drug cravings.
In healthy individuals, the Zika virus causes flu-like symptoms. If a pregnant woman becomes infected, the unborn child can suffer from severe brain abnormalities as a result of mechanisms that have not yet been explained. A study shows that Zika virus proteins bind to cellular proteins that are required for neural development.
A research team has revealed how cells in different parts of the human airway vary in their response to the common cold virus. Their finding could help solve the mystery of why some people exposed to the cold virus get ill while others don't, said the researchers.
New research shows that data routinely collected by health care companies -- if made available to researchers and public health agencies -- could enable more accurate forecasts of when the next flu season will peak, how long it will last and how many people will get sick.
A universal flu vaccine that protects people against most influenza strains is one step closer to reality. The candidate vaccine elicited a strong antibody response to a structure on the surface of flu viruses, called the hemagglutinin (HA) stalk. It protected mice from infection by various flu strains.
The critical, structural changes that enveloped viruses, such as HIV, Ebola and influenza, undergo before invading host cells have been revealed by scientists using nano-infrared spectroscopic imaging.
Adolescents who receive recommended vaccinations, including for human papillomavirus, have no increased risk of primary ovarian insufficiency, also known as premature menopause, according to a Kaiser Permanente study published today in Pediatrics.
The deadly Nipah virus and others like it assemble themselves in a much more haphazard manner than previously thought, new research has found. The discovery could allow scientists to develop more effective vaccines and rule out many approaches to fighting these viruses.
Obesity increases a person's risk for severe complications from influenza, including hospitalization and even death. It may also play a role in how flu spreads, according to a new study. The findings suggest that obese adults infected with flu shed the virus for a longer time than adults who are not obese, potentially increasing the opportunity for the infection to spread to others.
Virus-like particles (VLPs) are protein-based structures that mimic viruses and bind to antibodies. Because VLPs aren't infectious, they show promise as vaccine platforms for many viral diseases, including influenza. Since details about influenza VLPs are scant, a team of researchers developed a 3-D model based on the 1918 H1 pandemic influenza virus.
Changing public health messaging to focus on the impact of our actions -- for example, the potentially harmful impact of infecting a colleague with a cold, rather than whether we will infect them if we go into work in the first place -- could have significant implications for how we deal with global threats, according to a new study.
Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized controlled trial.
For the first time, scientists have directly visualized real-time structural changes in the surface protein of the influenza virus that may help the virus fuse with and enter target cells before hijacking them. Single molecules of the protein were found to stretch toward target cells, then refold and try again 5 to 10 times per second. The discovery may help develop more effective vaccines and better understand other viruses, including Ebola, HIV, and SARS.
The new influenza drug Xofluza was approved for clinical use in Japan in February 2018. Scientists have now investigated the drug's mode of action in detail, and uncovered possible mechanisms by which viral resistance to it could emerge.